See how research connects peptides to biological targets, signaling pathways, and biological processes.
This tool shows, for each peptide, which biological target the available research points to, how directly that relationship is supported, and how it connects to broader signaling pathways and biological processes. It describes what research suggests about biological mechanisms -- not proven health or treatment outcomes, and not medical advice. See each peptide's full research profile for complete detail, citations, and safety information.
The complete mechanism research history, including peptides outside the current catalog. Nothing here has been removed or invalidated -- it remains fully documented for reference.
Showing 83 of 83 peptides
Evidence legend
Relationship support
Directly supported
Supported indirectly
Inferred from related evidence
Uncertain
Evidence context
Human research
Preclinical research
Human + preclinical research
Review / established literature
Related compound/program context
Evidence context uncertain
Understanding mechanism evidence
This tool describes research into biological targets, signaling pathways, and biological processes -- not proven health or treatment outcomes, and not medical advice. Relationship-support and evidence-context labels describe the type and directness of research available, not proof of safety or effectiveness. See each peptide's full research profile for complete detail, citations, and safety information.
Mechanism profiles
Garetosmab
2 mechanism branches · Directly supported · Human + preclinical research
Signal / mechanism stepActivin A activates ActRIIA/ActRIIBActivin A normally binds activin type II receptors (ActRIIA/ActRIIB) -- the same receptors myostatin/GDF8 acts through.
Signal / mechanism stepSMAD2/SMAD3 signaling drives negative regulation of skeletal-muscle growthSMAD2/3 activation suppresses muscle-protein synthesis and myogenic transcriptional programs, restraining muscle-mass accrual.
Leads to
PathwayActivin & Myostatin Signaling
Relationship support in this pathway
Directly supported
Supported indirectly
Thin grey links (“Leads to”, “Contributes to”) show structure only and carry no support rating.
Relationship details
Garetosmab → Activin A — Directly supportedGaretosmab binds and inhibits Activin A, reducing its activation of activin type II receptors in muscle tissue.
Activin A activates ActRIIA/ActRIIB — Supported indirectlySources: SRC-TREVGARE-001
Downstream receptor/SMAD signaling steps reflect established TGF-beta-superfamily biology; the cited studies directly demonstrate garetosmab's combined-blockade human pharmacodynamic effect and a preclinical obesity-model bridge, not each individual biochemical step in isolation. This is a separate, investigational research context from garetosmab's FDA-approved FOP indication -- see the distinct FOP relationship record.
Sources
Central Citation Library reference: SRC-TREVGARE-001
Central Citation Library reference: SRC-TREVGARE-002
Looking for research areas instead?
Peptide Explorer shows what areas a peptide is researched in. This tool shows how the underlying biology appears to work.
Educational use only. Not medical advice. MitoCore Biosciences does not diagnose, treat, cure, prevent, prescribe, sell peptides, recommend dosing, or provide instructions for human use.
